JPM 2023：百济神州.pdf

1、Redefining Global BiotechJ A N U A RY 9,2 0 2 3J.P.Morgan 41stAnnual Healthcare ConferenceJP Morgan Healthcare Conference 2023Certain statements contained in this presentation and in the accompanying oral presentation,other than statements of fact that are independently verifiable at the date hereof

2、,may constitute forward-looking statements.Examples of such forward-looking statements include statements regarding BeiGenes research,discovery,and pre-clinical and early-stage clinical programs and plans;recent clinical data for BeiGenes product candidates and approvals of its medicines;the conduct

3、 of late-stage clinical trials and expected data readouts;additional planned commercial product launches;and the advancement of and anticipated clinical development,regulatory milestones and commercialization of BeiGenes medicines and drug candidates.Actual results may differ materially from those i

4、ndicated in the forward-looking statements as a result of various important factors,including BeiGenes ability to demonstrate the efficacy and safety of its drug candidates;the clinical results for its drug candidates,which may not support further development or marketing approval;actions of regulat

5、ory agencies,which may affect the initiation,timing and progress of clinical trials and marketing approval;BeiGenes ability to achieve commercial success for its marketed medicines and drug candidates,if approved;BeiGenes ability to obtain and maintain protection of intellectual property for its tec

6、hnology and medicines;BeiGenes reliance on third parties to conduct drug development,manufacturing and other services;BeiGenes limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete